Interleukin-6 in the cerebrospinal fluid after perinatal asphyxia is related to early and late neurological manifestations

Pediatrics

Volumn 100, Issue 5, 1997, Pages 789-794

  Martín Ancel, Ana ^a,c   García Alix, Alfredo ^b   Pascual Salcedo, Dora ^a   Cabañas, Fernando ^a   Valcarce, Manuel ^a   Quero, José ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

^c HOSPITAL INFANTIL LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ARTICLE; BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATORY CELL; MALE; NEUROLOGIC DISEASE; NEWBORN; OUTCOMES RESEARCH; PERINATAL ASPHYXIA; PRIORITY JOURNAL;

ASPHYXIA NEONATORUM; BRAIN DISEASES; BRAIN ISCHEMIA; HUMANS; INFANT, NEWBORN; INTERLEUKIN-6; NEUROLOGIC EXAMINATION;

EID: 1842370241     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.100.5.789     Document Type: Article

References (52)

1. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol. 1994;144:188-199
2. Konachek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke. 1992;23:1367-1379
3. McRae A, Gilland E, Bona E, Hagberg H. Microglia activation after neonatal hypoxia-ischemia. Dev Brain Res. 1995;84:245-252
4. Zhang RL, Chopp M, Jiang N, et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke. 1995;26:1438-1443
5. Wang X, Yue T-L, Barone FC, Feuerstein GZ. Monocyte chemoattractant protein-1 messenger RNA expression in rat ischemic cortex. Stroke. 1995;26:661-666
6. Minami M, Kuraishi Y, Yabuuchi K, Yamazaki A, Satoh M. Induction of interleukin-1β mRNA in rat brain after transient forebrain ischemia. J Neurochem. 1992;58:390-392
7. Hagberg H, Gilland E, Bona E, et al. Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats. Pediatr Res. 1996;40:603-609
8. Liu T, Clark RK, McDonnell PC, et al. Tumor necrosis factor-α expression in ischemic neurons. Stroke. 1994;25:1481-1488
9. Szaflarski J, Burtrum D, Silverstein FS. Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. Stroke. 1995;26: 1093-1100
10. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke. 1995;26:676-681
11. Garcia JH, Liu K-F, Relton JK. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol. 1995;147:1477-1486
12. Muraguchi A, Hirano T, Tang B, et al. The essential role of B-cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988;167:332-344
13. Nijsten MWN, De Groot ER, Ten Duis JH, Hack CE, Aarden LA. Serum levels of interleukin-6 and acute phase responses. Lancet. 1987;2:921
14. Ulich T, Yin S, Guo K, Yi ES, Remick D, del Castillo J. Intratracheal injection of endotoxin and cytokines: interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol. 1991;138: 1097-1101
15. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994; 83:113-118
16. Jirik FR, Podor TJ, Hirano T, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol. 1989;142:144-147
17. Youker K, Smith CW, Anderson DC, et al. Neutrophil adherence to isolated adult cardiac myocytes: induction by cardiac lymph collected during ischemia and reperfusion. J Clin Invest. 1992;89:602-609
18. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91:1520-1524
19. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. Induction of interleukin-6 synthesis in the myocardium: potential role in postreperfusion inflammatory injury. Circulation. 1995; 92:1866-1875
20. Maeda Y, Matsumoto M, Hori O, et al. Hypoxia/reoxygenation-mediated induction of astrocyte interleukin 6: a paracrine mechanism potentially enhancing neuron survival. J Exp Med. 1994;180:2297-2308
21. Wang X, Yue TL, Young PR, Barone FC, Feuerstein GZ. Expression of interleukin-6, c-fos, and zif268 mRNAs in rat ischemic cortex. J Cereb Blood Flow Metab. 1995;15:166-171
22. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 1995;26:1393-1398
23. García-Alix A, Cabañas F, Pellicer A, Hernanz A, Stiris TA, Quero J. Neuron-specific enolase and myelin basic protein: relationship of cerebrospinal fluid concentrations to the neurologic condition of asphyxiated full-term infants. Pediatrics. 1194;93:234-240
24. Martín-Ancel A, García-Alix A, Gayá F, Cabañas F, Burgueros M, Quero J. Multiple organ involvement in perinatal asphyxia. J Pediatr. 1995;127: 786-793
25. Dubowitz L, Dubowitz V. The Neurological Assessment of the Preterm and Full-Term Newborn Infant. Clinical Developmental Medicine, No. 79. London, England: Mac Keith Press; 1981
26. Amiel-Tison C, Ellison P. Birth asphyxia in the fullterm newborn: early assessment and outcome. Dev Med Child Neurol. 1986;28:671-682
27. Amiel-Tison C, Grenier A. Neurological Assessment During the First Year of Life. New York, NY: Oxford University Press; 1986
28. Frankenburg WK, Dodds JB. The Denver Developmental Screening Test. J Pediatr. 1967;71:181-191
29. Pellicer A, Cabañas F. Encefalopatía hipóxico-isquémica. In: Pérez Higueras A, Cabañas F, eds. Neuroultrasonografía Clínica. Madrid, Spain: Ediciones Norma; 1990:77-79
30. Lupton BA, Hill A, Roland EH, Whitfield MF, Flokmark O. Brain swelling in the asphyxiated term newborn: pathogenesis and outcome. Pediatrics. 1998;82:139-146
31. Helle M, Boeije L, Groot E, Vos A, Aarden L. Sensitive ELISA for interleukin-6. J Immunol Methods. 1991;138:47-56
32. Kharazmi A, Nielsen H, Rechnitzer C, Bendtzen K. Interleukin-6 primes human neutrophil and monocyte oxidative burst response. Immunol Lett. 1989;21:177-184
33. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol. 1990;144:129-135
34. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol. 1994;153:3811-3821
35. Touland S, Vige X, Fage D, Ben J. Local infusion of interleukin-6 attenuates the neurotoxic effect of NMDA on striatal cholinergic neurons. Neurosci Lett. 1992;144:49
36. Persson L, Hårdemark H-G, Gustafsson J, et al. S-100 and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987;18:911-918
37. Whitaker JN, Lisak RP, Bashir RM, et al. Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol. 1980;7:58-64
38. Strand T, Alling C, Karlsson B, Karlsson Y, Winbland B. Brain and plasma proteins in spinal fluid as markers for brain damage and severity of stroke. Stroke. 1984;15:138-144
39. Bauer J, Ganter U, Geiger T, et al. Regulation of interleukin-6 expression in cultured human monocytes and monocyte-derived macrophages. Blood. 1988;72:1134-1140
40. Cicco NA, Lindermann A, Content J, et al. Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. Blood. 1990;75:2049-2052
41. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;122:135-139
42. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995; 37:800-804
43. Peters AMJ, Bertram P, Gahr M, Speer CP. Reduced secretion of interleukin-1 and tumor necrosis factor-α by neonatal monocytes. Biol Neonate. 1993;63:157-162
44. lck modulation in CD3-or CD2-activated T cells from neonates. Pediatr Res. 1995;37:64-69
45. Satoh T, Nakamura S, Taga T, et al. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol. 1988;8:3546-3549
46. Hama T, Miyamoto M, Tsukui H, Nishio C, Hatanaka H. Interleukin 6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci Lett. 1989; 104:340-344
47. Mehler MI, Marmur R, Gross R, et al. Cytokines regulate the cellular phenotype of developing neural lineage species. Int J Dev Neurosci. 1995;13:213-240
48. Smith JW, Longo DL, Alvord WG, et al. Interleukin-1α treatment accelerates platelet recovery after high-dose carboplatin treatment. N Engl J Med. 1993;328:756-761
49. Fisher CJ Jr, Dhainault JF, Pribble JP, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Result of a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Study Group. JAMA. 1994;27:1836-1843
50. Nakata K, Kashimoto S, Yoshida H, Oku T, Nakamura S. Augmented antitumor effect of recombinant human interleukin-1α by indomethacin. Cancer Res. 1988;48:584-588
51. Elliot MJ, Maini RN, Feldman M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344: 1105-1110
52. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661